Background: One of the first line treatments for relapsingremitting multiple sclerosis (RRMS) is interferon-β (IFNb), a cytokine with immune-modulatory effects. There is a high degree of variability in the response to the drug which is, among other factors, due to the presence of neutralizing antibodies (NABs) occurring late during therapy. Methods: The objective of this study was to determine whether the response to IFNb therapy and NAB development can be predicted based on the expression levels of the type-I interferon receptors IFNAR1, IFNAR2a, IFNAR2b, and IFNAR2c before start of treatment. The IFNAR expression levels in 163 samples of patients with relapsing-remitting MS were measured by real-time polymerase chain reaction (PCR). Results: Pre-treatment IFNAR2c expression levels were somewhat lower in patients who developed NAB during treatment compared to NAB-negative patients. No significant differences in the expression levels of other IFNAR subtypes and isotypes were found. Baseline IFNAR levels were not predictive of the clinical response after 2 years.
Introduction
Interferon-β (IFNb) has been used in the treatment of MS for roughly 20 years. It acts by binding to the specific receptor (IFNAR) leading to activation of cytoplasmic signal transducers and kinases ultimately controlling thousands of genes [1] [2] [3] . The IFNAR comprises 2 subunits, IFNAR1 and IFNAR2. The subunits are detached in the membrane and combine during the binding process of IFNb forming a stable complex [2, [4] [5] [6] [7] .
IFNAR2, the major ligand binding subunit, can be expressed in three different isoforms; the IFNAR2a-isoform (or IFNAR2.3) is regarded as a soluble receptor subunit and has been found in different body fluids. Furthermore, there are the IFNAR2b-isoform (or IFNAR2.1), the transmembrane short form, and the IFNAR2c-isoform (or IFNAR2.2), the transmembrane long subunit [2, [7] [8] [9] [10] . IFNAR2b consists of a truncated cytoplasmic tail and therefore, is unable to perform signal transduction [2, 8, 11] while the functional isoform IFNAR2c is able to perform signal transduction [2, 12, 13] .
Due to a high degree of variability of the IFNb response and the fact that therapy failure is usually only detected more than one year after therapy [14] , the aim of our study was to test if the IFNb response can be predicted by IFNAR expression levels before treatment using NAB development, MxA levels at baseline (a reliable biomarker to evaluate IFNb bioactivity [15, 16] ), and the clinical outcome as endpoints. Similar studies have been performed previously in retrospective analyses not showing a predictive value of pre-treatment IFNAR expression on NAB development [17] . However, here we have also investigated IFNAR expression in context with clinical endpoints in a prospective setting.
Materials and methods

Study population
This study included 163 patients with definite relapsing-remitting MS according to the McDonald criteria [18] . For this work the majority of samples with data on NAB and clinical status from a previous study (NABINMS [19] [19] .
Patients were followed for at least 2 years with visits at baseline, 3, 12 and 24 months on treatment. Blood was collected at all visits. A patient was considered NAB positive if NAB were present at 24 months. Clinical non-response was defined as an increase of at least one step on the expanded disability status scale (EDSS) confirmed at 6 months OR a decrease in relapse rate of less than 50% compared with 2 years before therapy.
One step EDSS increase was defined as an increase in EDSS of 1.5 points for patients with baseline EDSS score of 0; 1 point for scores from 1.0 to 5.0; 0.5 points for scores equal or higher to 5.5 [20] .
NAB tests were done as previously described [19] .
IFNAR1, IFNAR2 isoforms and MxA quantification
After spectrophotometric quantification at 260 and 280 nm, 10 ng of total RNA, extracted from whole blood, was reversely transcribed with the High Capacity Reverse Transcription Kit (Applied Biosystems, Thermo Fisher Scientific, Waltham, MA, USA). After that polymerase chain reaction (PCR) was performed using the Applied Biosystems -7300 real-time PCR system and ABI Prism 7000 Sequence Detection System (Thermo Fisher Scientific, Waltham, MA, USA). MxA, an indicator of IFNb bioavailability [15, 16] , was measured by real-time PCR also using the TaqMan Assay-on demand gene expression kit (Hs00182073_m1; Thermo Fisher Scientific, Waltham, MA, USA). All PCR reactions were set up in 96 well plates with a final volume of 25 μL and the cDNA in a concentration of 10 ng.
PCR amplification started with a first step at 50 °C for 2 min and continued with a heating step at 95 °C for 10 min. This was followed by the elongation, annealing and elongation steps at 95 ° for 15 s and 60 °C for 1 min. For all receptors 40 cycles were chosen, except 50 cycles for the IFNAR2a (2.3) receptor.
Results were expressed as ΔCt, which is the difference of the target gene and the ΔCt of the housekeeping gene. In our work 18S rRNA (VIC) was used as housekeeping gene for reference.
To reduce the effect of varying mRNA amount in PCR on the results, the ΔCt-method was favored to the raw Ct-values.
Of note, the lower the ΔCt-value the higher the expression level.
Statistical methods
Data were analysed using nonparametric statistical tests and are described as median and inter-quartile ranges (IQR) between 10% and 90% percentile as well as ranges.
Comparisons between two groups were performed using the Mann-Whitney U test. Furthermore, a receiver operating characteristics (ROC) analysis was calculated for the determination of likelihood ratio, sensitivity, and specificity. All reported p-values are based on two-tailed statistical tests. p-Values of < 0.05 were considered significant. All analyses were performed using GraphPad PRISM, version 5.03 (GraphPad Software, La Jolla, CA, USA).
Ethics
The study has been approved by the Ethical Committees of all participating centers. All subjects signed the informed consent form before participation. The study was performed in accordance with the declaration of Helsinki.
Results
At baseline, all patients were negative for NABs. In 19 (11.7%) patients neutralizing antibodies (NAB) occurred during treatment and 144 (88.3%) were NAB-negative at every time when blood was collected. There were no transient NAB-positive patients.
In a subset of 124 patients (17 of whom were NABpositive) with available clinical data, 60 (48.4%) were classified as clinical non-responders and 64 (51.6%) patients as responders, based on the criteria described in the Materials and methods -Study population section.
Ten (15.6%) patients in the responder-group and seven (11.7%) patients in the non-responder-group were NAB-positive.
Of these 124 patients 65 received IM-IFNb-1a (52%), 30 patients were treated with IFNb-1b (24%), and 29 patients with SC-IFNb-1a (23%).
In the responder-group, 10 patients developed NABs (eight on IFNb-1b, one on each of the other IFNb preparations), whereas seven of the 60 non-responders were NABpositive (all on IFNb-1b).
The number of patients on each IFNb preparation and NAB as well as clinical responder status are shown in Table 1 . The number of patients on the different IFNb preparations did not differ significantly between responders and non-responders.
There were no significant differences in the median basal expression of IFNAR1, IFNAR2a and IFNAR2b (p ≥ 0.32) between NAB+ and NAB-patients (Table 2) . This also applies to the MxA expression between the two groups of patients (p = 0.56). IFNAR2c expression levels were slightly lower in NAB+ compared to NAB-patients (p = 0.07; Figure 1 ).
ROC analysis for IFNAR1, IFNAR2a and IFNAR2b showed a poor performance (AUC ≤ 0.55). For IFNAR2c ΔCt-levels of > 16.42 the sensitivity in predicting NAB development was 68% and the specificity was 72% with a likelihood ratio of 2.40 (AUC 0.63, p = 0.068).
The basal IFNAR expressions of all isoforms did not differ significantly based on the clinical response-status after 24 months of treatment.
Correlations between MxA and different IFNAR expression levels are shown in Table 3 . In summary, IFNAR1 levels correlated weakly and negatively with MxA (r Spearman = -0.165; p = 0.035), whereas there was no correlation between MxA and the different IFNAR2 isotypes. IFNAR1 and the different IFNAR2 isotypes correlated significantly, however weakly to moderately, with each other.
Discussion
We found that the clinical response to IFNb based on EDSS and relapse rates, as well as development of NABs, cannot be reliably predicted through the basal expression of IFNb-receptors.
IFNAR2c was the only isoform that had some predictive value for NAB development with a borderline p-value. NAB-positive patients had lower pre-treatment IFNAR2c expression levels than NAB-negative subjects. Similarly, Gilli et al. [17] found a significantly lower expression of IFNAR2c in NAB-positive patients. One explanation is the hypothesis of hyperstimulation stating that a lower binding capacity leads to higher free IFNb levels promoting an anti-IFNb immune response. One reason why we did not find such a strong effect as Gilli et al. might be that we extracted mRNA from whole blood including granulocytes rather than from PBMCs.
The number of NAB-positive patients per IFNb preparation is slightly distorted towards IFNb-1b resulting in an under-representation of IFNb-1a preparations. At least NAB-positive rates in patients treated with IM-IFNb-1a were as expected [21, 22] . One of the imminent problems when using NAB as an outcome is the distribution of IFNb preparations in the study population. In particular, IMIFNb-1a rarely induces NAB. If patients on this IFNb preparation had been treated with a more immunogenic IFNb, the NAB-positive rate would have been correspondingly higher. As NAB-positive rates were very low in SC-IFNb-1a and IM-IFNb-1a patients, we could not perform a separate analysis in these groups. However, if analyzing IFNb-1b treated patients only we found no significant difference of pre-treatment IFNAR expression levels between NABpositive and negative patients (data not shown).
Among the different isoforms IFNAR2c is expressed at the highest levels ( Figure 2 ). This can be interpreted in view of the functional role of IFNAR2c being the crucial subunit for the IFNb response. Moreover, its response seems more important than the protection of the IFNb bound from degradation through IFNAR2a [23] . It has been suggested that the therapeutic effect of IFNb-therapy is associated with the relatively high baseline expression of the IFNAR2c [17] . Our data suggest that IFNARs are regulated agonistic. There was a significant and strong correlation between the IFNAR subunits and isotypes in a non-stimulated setting. Upon receptor activation this pattern changes with downregulation of the IFNAR2b and -2c receptors and up-regulation of IFNAR2a as a regulatory factor [17] .
We found only a weak correlation between MxA and IFNAR expression levels which probably reflects the nonstimulated status of IFNARs in untreated patients.
We could not detect a predictive value of MxA expression level in pre-treatment relapsing-remitting multiple sclerosis (RRMS)-patients. This is in line with previous observations by Oliver et al. [24] and can be explained by the fact that MxA is a marker of IFNAR activation and does not correlate with IFNAR baseline expression levels. One study showed a positive correlation between the clinical response and MxA expression during IFNb treatment [25] , although the results might have been confounded by NABs.
In a study by Hundeshagen et al. [26] , neither the number of relapses nor the increase in EDSS differed between patients with high and low MxA levels at baseline which is in line with the present results.
Unfortunately, we could not detect a difference of baseline IFNAR levels between clinical responders and non-responders. In contrast, a study by Comabella et al. [27] showed elevated expression of CD14+ specific IFNAR1 in IFNb non-responders compared to responders which was later validated by Bustamante et al. [28] . One could argue that cell type restricted IFNAR expression might better predict IFNb. However, the above results should be confirmed by an independent group. Serana et al. [29] found the same trend in IFNAR ΔCt-value distribution (Figure 2) , except for the fact that their ΔCt-values were markedly lower than ours. However, due to the fact that Serena et al. used GAPDH as the housekeeping gene, with a different expression-value level than 18S, they received lower ΔCt-values compared to our ΔCt-values. Limitations need to be mentioned, such as the low number of NAB-positive patients which may have influenced the statistics. As this project was originally designed as an exploratory study [19] , a formal pre-study power calculation was not performed, mainly because there were no clear assumptions of expected differences between groups.
Other factors such as the genetic background, including IFNAR1 and IFNAR2 polymorphisms and human leukocyte antigen (HLA) status, need to be considered but could not be determined due to limited sample material. In fact, HLA-DRB1*0401 and HLA-DRB1*0408 are strongly associated with NAB development [30] . In context with IFNAR expression levels, this association might become even stronger.
Finally, we showed that the clinical response to interferon-therapy of multiple sclerosis patients cannot be predicted through the basal expression of interferonreceptors. However, there were somewhat lower pretreatment IFNAR2c concentrations in later NAB-positive patients indicating a possible role of this IFNAR isotype in the regulation of IFNb bioactivity. 
